Fox Run Management, L.L.C. Astria Therapeutics, Inc. Transaction History
Fox Run Management, L.L.C.
- $608 Million
- Q1 2025
A detailed history of Fox Run Management, L.L.C. transactions in Astria Therapeutics, Inc. stock. As of the latest transaction made, Fox Run Management, L.L.C. holds 34,320 shares of ATXS stock, worth $169,884. This represents 0.03% of its overall portfolio holdings.
Number of Shares
34,320Holding current value
$169,884% of portfolio
0.03%Shares
1 transactions
Others Institutions Holding ATXS
# of Institutions
119Shares Held
51.1MCall Options Held
5.3KPut Options Held
6.1K-
Perceptive Advisors LLC New York, NY6.49MShares$32.1 Million1.45% of portfolio
-
Ra Capital Management, L.P. Boston, MA5.11MShares$25.3 Million0.57% of portfolio
-
Vestal Point Capital, LP New York, NY4.18MShares$20.7 Million1.59% of portfolio
-
Fcpm Iii Services B.V. Naarden, P73.82MShares$18.9 Million4.93% of portfolio
-
Fairmount Funds Management LLC Philadelphia, PA3.55MShares$17.6 Million6.47% of portfolio
About Astria Therapeutics, Inc.
- Ticker ATXS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 15,178,000
- Market Cap $75.1M
- Description
- Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare and niche allergic, and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in preclinical development stage...